Plaque Psoriasis Drug MOA Animation

Created for Arcutis Biotherapeutics
The project

In this plaque psoriasis drug MOA animation created for dermatologists, we present the innovative drug delivery mechanism of Zoryve. In dermatology, the role of the proinflammatory enzyme phosphodiesterase 4 (PDE4) in plaque psoriasis psoriasis is well established. However, inhibiting PDE4 with topical drugs has so far been unsuccessful. This is due to the difficulty in crossing the epidermis without disrupting its barrier function. Arcutis solved this with a novel formulation of roflumilast that facilitates delivery to the cells driving inflammation in plaque psoriasis. To explain this innovative drug delivery process, we worked with Arcutis scientists and devised a visual model of the emulsions that house roflumilast. We then sectioned these emulsions and the lipid matrix between corneocytes. Next, we animated the roflumilast molecules diffusing passively between stratum corneum cells to reach their target. In a second plaque psoriasis drug MOA animation (not shown), our medical animators depict how roflumilast acts to inhibit PDE4 activity.

Created for
Arcutis Biotherapeutics